Literature DB >> 26980039

A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.

Noreen M Walsh1, Kirsten E Fleming2, John G Hanly3, Kelly Dakin Hache2, Steve Doucette4, Gerardo Ferrara5, Lorenzo Cerroni6.   

Abstract

The susceptibility of Merkel cell carcinoma to the host immune response has prompted a search for effective immunotherapy. CD8-positive T lymphocytes are considered key effectors of this response, but the cellular infiltrates also harbor tumor-protective agents. By developing a comprehensive morphological and immunophenotypic map of tumor-infiltrating lymphocytes (TILS) in Merkel cell carcinoma, we aimed to establish a useful template for future studies. Twenty-two cases (mean age, 79years [range, 52-95]; male-female ratio, 10:12) were studied. TILS were categorized as brisk (7), nonbrisk (9), and absent(6). Merkel cell polyomavirus (MCPyV)-positive (16) and -negative (6) cases were included, as were those with pure (18) and combined (4) morphologies. One MCPyV+ case had undergone spontaneous regression. Immunohistochemical markers included CD3, CD4, CD8, CD20, CD68, FoxP3, PD-1, and CD123. Statistical analysis used Fisher exact tests and Spearman correlations. There was a significant correlation between brisk TILs and MCPyV+ status (P=.025). CD8+ T lymphocytes predominated, were present in significantly higher proportions in brisk infiltrates (P=.003), and showed a significant predilection for the intratumoral environment (P=.003). Immune inhibitors including T regulatory cells (FOXP3+) and PD-1+ "exhausted" immunocytes were present in lower proportions. Our findings support (1) the link between a brisk immune response and MCPyV positivity, (2) the supremacy of CD8+ cells in effecting immunity, and (3) the incorporation of immune inhibitors within the global infiltrate. Efforts to therapeutically arm the "effectors" and disarm the "detractors" are well focused. These will likely have the greatest impact on MCPyV-positive cases.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antitumoral immunity; Cutaneous neuroendocrine carcinoma; Merkel cell carcinoma; PD-1/PD-L1 pathway; TILS; Tumor-infiltrating lymphocytes; Tumor-specific CD8+ T cells

Mesh:

Substances:

Year:  2016        PMID: 26980039     DOI: 10.1016/j.humpath.2016.02.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma.

Authors:  Anish A Butala; Varsha Jain; Vishruth K Reddy; Ronnie A Sebro; Yun Song; Giorgos Karakousis; Tara C Mitchell; J Nicholas Lukens; Jacob E Shabason
Journal:  Oncologist       Date:  2020-09-17

2.  RB1-deficient squamous cell carcinoma: the proposed source of combined Merkel cell carcinoma.

Authors:  Ryan C DeCoste; Noreen M Walsh; Daniel Gaston; Thai Yen Ly; Sylvia Pasternak; Sam Cutler; Mat Nightingale; Michael D Carter
Journal:  Mod Pathol       Date:  2022-09-08       Impact factor: 8.209

Review 3.  Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Authors:  Daniela Femia; Natalie Prinzi; Andrea Anichini; Roberta Mortarini; Federico Nichetti; Francesca Corti; Martina Torchio; Giorgia Peverelli; Filippo Pagani; Andrea Maurichi; Ilaria Mattavelli; Massimo Milione; Nice Bedini; Ambra Corti; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 4.  Merkel cell carcinoma.

Authors:  Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem
Journal:  Nat Rev Dis Primers       Date:  2017-10-26       Impact factor: 52.329

5.  Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.

Authors:  Cathrin Ritter; Kaiji Fan; Annette Paschen; Sine Reker Hardrup; Soldano Ferrone; Paul Nghiem; Selma Ugurel; David Schrama; Jürgen C Becker
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

6.  PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.

Authors:  Angela Lamarca; Daisuke Nonaka; Wolfgang Breitwieser; Garry Ashton; Jorge Barriuso; Mairéad G McNamara; Sharzad Moghadam; Jane Rogan; Wasat Mansoor; Richard A Hubner; Christopher Clark; Bipasha Chakrabarty; Juan W Valle
Journal:  Oncotarget       Date:  2018-02-12

7.  Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53.

Authors:  Kaiji Fan; Ivelina Spassova; Jan Gravemeyer; Cathrin Ritter; Kai Horny; Anja Lange; Thilo Gambichler; Niels Ødum; David Schrama; Dirk Schadendorf; Selma Ugurel; Jürgen C Becker
Journal:  Oncogene       Date:  2020-12-11       Impact factor: 9.867

Review 8.  Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.

Authors:  Karolina Stachyra; Monika Dudzisz-Śledź; Elżbieta Bylina; Anna Szumera-Ciećkiewicz; Mateusz J Spałek; Ewa Bartnik; Piotr Rutkowski; Anna M Czarnecka
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

9.  Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.

Authors:  Nicolas A Giraldo; Peter Nguyen; Elizabeth L Engle; Genevieve J Kaunitz; Tricia R Cottrell; Sneha Berry; Benjamin Green; Abha Soni; Jonathan D Cuda; Julie E Stein; Joel C Sunshine; Farah Succaria; Haiying Xu; Aleksandra Ogurtsova; Ludmila Danilova; Candice D Church; Natalie J Miller; Steve Fling; Lisa Lundgren; Nirasha Ramchurren; Jennifer H Yearley; Evan J Lipson; Mac Cheever; Robert A Anders; Paul T Nghiem; Suzanne L Topalian; Janis M Taube
Journal:  J Immunother Cancer       Date:  2018-10-01       Impact factor: 13.751

10.  Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.

Authors:  Piotr Donizy; Cheng-Lin Wu; Janusz Kopczynski; Malgorzata Pieniazek; Przemyslaw Biecek; Janusz Ryś; Mai P Hoang
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.